<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Discharge 2014: Innovative Medicines Initiative 2 Joint Undertaking (IMI) (A8-0081/2016 - Marian-Jean Marinescu) - Thursday, 28 April 2016</title><meta name="title" content="Verbatim report of proceedings - Discharge 2014: Innovative Medicines Initiative 2 Joint Undertaking (IMI) (A8-0081/2016 - Marian-Jean Marinescu) - Thursday, 28 April 2016" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2016 - Source: European Parliament" /><meta name="available" content="28-04-2016" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Discharge 2014: Innovative Medicines Initiative 2 Joint Undertaking (IMI) (A8-0081/2016 - Marian-Jean Marinescu) - Thursday, 28 April 2016" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2016-04-28-ITM-005-61_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2016-04-28-ITM-005-61_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-04-28-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-04-28-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-04-28-ITM-005-60_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-04-28-ITM-005-60_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2016-04-28-ITM-005-62_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2016-04-28-ITM-005-62_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-04-28_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-04-28_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2015/2200(DEC)">2015/2200(DEC)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A8-0081/2016</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-8-2016-0081_EN.html" class="ring_ref_link">A8-0081/2016</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-8-2016-04-27-ITM-017_EN.html" class="ring_ref_link">PV 27/04/2016 - 17</a><br />
                        <a href="/doceo/document/CRE-8-2016-04-27-ITM-017_EN.html" class="ring_ref_link">CRE 27/04/2016 - 17</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-8-2016-04-28-ITM-004-61_EN.html" class="ring_ref_link">PV 28/04/2016 - 4.61</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-8-2016-0197_EN.html" class="ring_ref_link">P8_TA(2016)0197</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 28 April 2016 - Brussels</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 5.61. Discharge 2014: Innovative Medicines Initiative 2 Joint Undertaking (IMI) (<a href="/doceo/document/A-8-2016-0081_EN.html">A8-0081/2016</a> - Marian-Jean Marinescu)</td></tr></table>
<a name="2-1761-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Schriftliche Stimmerklärungen</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0187"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124831.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Isabella Adinolfi (EFDD), </span></span>  <span class="italic">per iscritto. ‒ </span>L'impresa comune per l'iniziativa in materia di medicinali innovativi 2 è una partnership tra il settore pubblico e privato per il campo della farmaceutica. La relazione riporta che l'impresa comune ha completato un audit sul monitoraggio e ha presentato relazioni sulla performance operativa. L'impresa comune ha dato inoltre seguito a tutte le raccomandazioni. L'impresa ha inoltre pubblicato, nel febbraio 2016, una breve analisi sui risultati dei progetti dell'impresa comune e degli effetti socioeconomici. Tuttavia i potenziali conflitti di interessi mi hanno portato a votare negativamente al discarico.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0218"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125048.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marina Albiol Guzmán (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>IMI es una Empresa Común dedica a la innovación médica. Debido a la vaguedad con la que se nos presenta su contabilidad y el hecho que la UE ha adoptado un modelo de innovación médica que privilegia los ingresos de las farmacéuticas frente a la salud pública, he decidido votar en contra de la decisión presupuestaria, votando a favor de la resolución final.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0226"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113959.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Martina Anderson (GUE/NGL),</span></span>   <span class="italic">in writing</span><span class="bold">. </span>– This JU is aimed at improving the efficiency and effectiveness of the drug development process for the production of safer innovative medicines. While the accounts gave a fair representation of the JU’s financial position, the ex-ante control performed by the Joint Undertaking’s Scientific Project Officers (SPO) did not clearly identify and comment upon the status of the project and its deliverables; and payment was made without an official listing of deliverables accepted by the SPO and without any reference to the assessment of deliverables by the SPO. Therefore I voted in favour of discharge but abstained on the approval of accounts.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0234"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125110.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νίκος Ανδρουλάκης (S&amp;D), </span></span>  <span class="italic">γραπτώς. ‒ </span>Υπερψήφισα την έκθεση σχετικά με την απαλλαγή όσον αφορά την εκτέλεση του προϋπολογισμού της Κοινής Επιχείρησης Πρωτοβουλία για καινοτόμα φάρμακα 2 (πρώην κοινή επιχείρηση για την υλοποίηση της κοινής τεχνολογικής πρωτοβουλίας για τα καινοτόμα φάρμακα) για το οικονομικό έτος 2014, διότι στο πλαίσιο των κοινών επιχειρήσεων η βιομηχανία συνδέεται με την έρευνα στην κατεύθυνση της υποστήριξης νέων τεχνολογιών. Επιπρόσθετα, η συγκεκριμένη έκθεση συμπεριλαμβάνει διάφορες ενέργειες για την εισαγωγή στην αγορά εξειδικευμένων τεχνολογιών</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0242"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marie-Christine Arnautu (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Les données d'évaluation fournies sont pour le moins brouillon... J'ai donc voté contre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124958.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jonathan Arnott (EFDD), </span></span>  <span class="italic">in writing. ‒ </span>I voted against discharge on the grounds that I disapprove of the European Union, and consequently I disapprove of the expenditure in this area.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124773.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean Arthuis (ALDE), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai voté en faveur de cette résolution comme le préconisait la commission compétente au fond.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96680.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zigmantas Balčytis (S&amp;D), </span></span>  <span class="italic">raštu. ‒ </span>Balsavau už 2014 m. biudžeto įvykdymo ataskaitos patvirtinimą II naujoviškų vaistų iniciatyvos bendrajai įmonei. Audito Rūmai savo ataskaitoje pažymi, jog jie gavo pagrįstą patikinimą, kad Įmonės metinės finansinės ataskaitos yra patikimos ir kad jose nurodytos operacijos yra teisėtos ir tvarkingos. Tačiau Europos Parlamentas apgailestauja, kad nepakanka informacijos, susijusios su nepiniginiais ar grynųjų pinigų įnašais, todėl pritariu Europos Parlamento raginimui, kad Audito Rūmai į būsimas ataskaitas įtrauktų konkrečias nuostatas dėl vertinimo procedūros ir atskirai BP 7 ir programai „Horizontas 2020“ nustatytų nepiniginių ir grynųjų pinigų įnašų lygio. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96877.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zoltán Balczó (NI), </span></span>  <span class="italic">írásban. ‒ </span>A jelentéstevő aggodalommal állapítja meg, hogy a projektköltségek kifizetésére vonatkozó operatív előzetes ellenőrzések elvégzését nem dokumentálták megfelelően. Megjegyzi még, hogy a közös vállalkozás tudományos tisztviselői által végzett előzetes ellenőrzés nem azonosította és észrevételezte a projektek helyzetét (folyamatban, hiányosságokkal folyamatban, felfüggesztve/törölve) és azok konkrét eredményeit (nincs fenntartás, pontosítást igénylő fenntartás, jelentős fenntartás). Kiemeli, hogy a konkrét eredményeket felsoroló, a tudományos tisztviselő által elfogadott hivatalos jegyzék nélkül több esetben történt kifizetés. </p>
<p class="contents">Fontos továbbá megjegyezni, hogy a Hetedik Keretprogram és a Horizont 2020 keretprogram végrehajtásával kapcsolatos információk egyértelmű elválasztása hiányában az operatív tevékenységre vonatkozó felhasználási és kötelezettségvállalási mutatók nem biztosítják a teljesítmény valódi értékelését. Ehhez kapcsolódóan kiemelt hiányosságként említi a jelentéstevő, hogy az e két programra vonatkozó kötelezettségvállalási előirányzatok és a kifizetési előirányzatok nem elkülönítve szerepelnek az éves tevékenységi jelentésben. Így átláthatatlanná és ellenőrizhetetlenné vált a közös vállalkozás eredményességi mutatóinak az értékelése. Fontos kiemelni a jelentés egy mondatát, melyben a jelentéstevő összegzi, hogy nem áll rendelkezésre információ a természetbeni és pénzbeli hozzájárulásokról, mely a korrupcióellenes és az átlátható működés minimum feltételeit sem biztosítja a közös vállalkozásnál. Fentiek figyelembe vétele mellett szavazatommal a mentesítést nem támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0125"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124760.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicolas Bay (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Ce rapport appelle à octroyer la décharge sur l'exécution du budget de l'entreprise commune "Initiative en matière de médicaments innovants 2" (IMI), établie en vue de poursuivre et prolonger l'activité de la précédente, intitulée "entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants". Le rapport souligne que la répartition des engagements n'est pas clairement indiquée dans le rapport de gestion: dépendent-ils du nouveau programme ou de l'ancien (le 7e programme pluriannuel). Ceci rend l'évaluation et l'audit de l'entreprise commune incertains. </p>
<p class="contents">Pour autant, l'entreprise commune aurait su mener à bien quelques corrections suggérées précédemment par la Cour, notamment la publication des déclarations de non conflits d'intérêts des dirigeants. Enfin, quoiqu'elle n'ait pas fourni de chiffres clairs à partir desquels évaluer son activité ou son efficacité, l'entreprise commune fait l'objet d'un rapport bienveillant et peu critique. J'ai donc voté contre ce rapport. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125002.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Hugues Bayet (S&amp;D), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai approuvé ce rapport de la commission du contrôle budgétaire qui appelait à octroyer la décharge sur l'exécution du budget 2014 à l'entreprise commune "Initiative en matière de médicaments innovants 2".</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0312"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124867.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Brando Benifei (S&amp;D), </span></span>  <span class="italic">per iscritto. ‒ </span>La procedura di discarico del bilancio rappresenta un momento importante nella vita istituzionale dell'Unione europea. In questa occasione il Parlamento europeo, unica istituzione eletta a suffragio universale dai cittadini, decide su raccomandazione del Consiglio se garantire o meno l'approvazione definitiva dell'esecuzione del bilancio per un determinato esercizio finanziario. Si tratta di un passaggio fondamentale che è anche l'occasione per indirizzare specifiche raccomandazioni alle istituzioni e alle agenzie che compongono la struttura comunitaria. Seguendo le indicazioni della commissione per il controllo dei bilanci (CONT), oggi ho deciso di votare a favore della relazione Marinescu sul discarico del bilancio del 2014 per l'impresa comune per l'Iniziativa in materia di medicinali innovativi 2</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0343"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/135490.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Xabier Benito Ziluaga (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>Se ha votado a favor de la aprobación la gestión y del cierre de cuentas al no encontrarse irregularidades reseñables. Ahora bien, es preciso señalar, como en el caso restante de las Joint Undertakings, que mantenemos una posición crítica sobre las mismas en tanto que la participación público-privada supone una privatización de los rendimientos y una mercantilización de actividades de utilidad pública.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124771.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dominique Bilde (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Du fait du caractère incertain de l'évaluation et de l'audit de cette entreprise commune, je ne pouvais pas être favorable à l'octroi d'une décharge sur l'exécution de son budget pour l'exercice 2014.</p>
<p class="contents">La répartition des engagements n'est pas clairement définie: on ne sait s'ils dépendent du nouveau programme ou du 7e programme pluriannuel.</p>
<p class="contents">Une nouvelle fois, aucun chiffre clair n'a été fourni pour mesurer l'efficacité de cette entreprise ou mesurer ses activités, ce qui est problématique quand on sait que son budget a été porté à 1,6 milliard dans le programme pluriannuel Horizon 2020.</p>
<p class="contents">Pour autant, le rapport se veut complaisant. Je ne pouvais donc le soutenir.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (ENF), </span></span>  <span class="italic">per iscritto. ‒ </span>Non concordo con le posizioni sostenute nella relazione Marinescu. Ho quindi deciso di non votare a favore del discarico dell'impresa comune Iniziativa medicinali innovativi (IMI).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96681.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vilija Blinkevičiūtė (S&amp;D), </span></span>  <span class="italic">raštu. ‒ </span>Balsavau dėl šio pranešimo, nes juo Parlamentas II naujoviškų vaistų iniciatyvos bendrosios įmonės vykdomajam direktoriui patvirtina, kad Bendrosios įmonės 2014 finansinių metų biudžetas įvykdytas. Bendroji įmonė siekiant įgyvendinti jungtinę technologijų iniciatyvą „Naujoviški vaistai“ įsteigta 2007 m. dešimties metų laikotarpiui siekiant gerokai pagerinti vaistų kūrimo proceso efektyvumą bei veiksmingumą ir įgyvendinti ilgalaikį tikslą, kad farmacijos sektorius gamintų veiksmingesnius ir saugesnius naujoviškus vaistus. Parlamentas savo rezoliucijoje pažymi, kad Audito Rūmų ataskaita pagrįsta pernelyg dideliu skaičiumi bendro pobūdžio pastabų ir pateikiama pernelyg mažai pagrįstų ir konkrečių pastabų, todėl ragina atlikti auditą, kuris būtų labiau sutelktas į metinę finansinę veiklą, daugiamečių projektų įgyvendinimo būklę (įskaitant aiškų atitinkamų metų ir ankstesnių metų biudžeto įgyvendinimo pristatymą) ir jų įgyvendinimo rezultatus.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0812"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125004.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Franc Bogovič (PPE), </span></span>  <span class="italic">pisno. ‒ </span>Podprl sem tudi predlog sklepa Evropskega parlamenta o razrešnici glede izvrševanja proračuna Skupnega podjetja za pobudo za inovativna zdravila 2, za proračunsko leto 2014, na podlagi upoštevanja izjave o zanesljivosti računovodskih izkazov ter zakonitosti in pravilnosti z njimi povezanih transakcij, ki jo je za proračunsko leto 2014 v skladu s členom 287 Pogodbe o delovanju Evropske unije pripravilo Računsko sodišče.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0827"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124984.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lynn Boylan (GUE/NGL),</span></span>   <span class="italic">in writing</span><span class="bold">. </span>– This joint undertaking is aimed at improving the efficiency and effectiveness of the drug development process for the production of safer innovative medicines. While the accounts gave a fair representation of the joint undertaking’s financial position, the ex-ante control performed by the joint undertaking's Scientific Project Officers (SPO) did not clearly identify and comment upon the status of the project and its deliverables, and payment was made without an official listing of deliverables accepted by the SPO and without any reference to the assessment of deliverables by the SPO. Therefore I voted in favour of discharge but abstained on the approval of accounts.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0843"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28346.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mercedes Bresso (S&amp;D), </span></span>  <span class="italic">per iscritto. ‒ </span>Ho votato a favore de discarico di bilancio 2014 dell'impresa comune per l'Iniziativa in materia di medicinali innovativi 2 (IMI) perché ritengo che le sue finanze siano state gestite in maniera oculata e compatibile con le previsioni del bilancio per l'anno in questione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124787.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Renata Briano (S&amp;D), </span></span>  <span class="italic">per iscritto. ‒ </span>La procedura di discarico è uno strumento fondamentale nelle mani del Parlamento europeo per vigilare sull'esecuzione del bilancio delle diverse istituzioni e agenzie europee ed effettuare così un controllo politico approfondito sull'impiego dei fondi pubblici.</p>
<p class="contents">Si tratta di una prassi consolidata, essenziale per garantire la trasparenza e la responsabilità democratica delle istituzioni nei confronti dei contribuenti dell'UE.</p>
<p class="contents">Affinché tale prerogativa sia esercitata pienamente, occorre tuttavia che l'insieme delle istituzioni europee collabori in maniera aperta e costruttiva con la commissione per il controllo dei bilanci del Parlamento europeo, fornendo tutte le informazioni e i documenti necessari, rispondendo alle interrogazioni scritte e partecipando alle audizioni e alle discussioni sull'esecuzione del bilancio previste. </p>
<p class="contents">In tal senso, se da un lato la maggior parte delle istituzioni dimostra un atteggiamento cooperativo facilitando il controllo del Parlamento sull'esecuzione del loro bilancio, alcune istituzioni non collaborano in maniera soddisfacente, violando i principi di leale cooperazione e di trasparenza sanciti dai trattati. Penso in particolare al Consiglio, il quale dal 2009 si rifiuta di sottoporsi all'esercizio di discarico, eludendo di fatto il controllo politico su oltre 3 miliardi di fondi pubblici europei spesi, alimentando così il sentimento di sfiducia nei confronti delle istituzioni europee.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0906"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124869.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gianluca Buonanno (ENF), </span></span>  <span class="italic">per iscritto. ‒ </span>Voto contrario, poiché la risoluzione è a sostegno della concessione del discarico all’impresa comune sui medicinali innovativi, istituita nel 2014 nell'ambito del settimo programma quadro. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0921"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124851.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicola Caputo (S&amp;D), </span></span>  <span class="italic">per iscritto. ‒ </span>Oggi ho votato a favore della relazione in questione perché dalla documentazione esaminata si evince che i conti dell'impresa comune per l'iniziativa in materia di medicinali innovativi 2 sono da ritenersi pienamente affidabili. L'impresa comune per l'iniziativa in materia di medicinali innovativi 2 ("impresa comune IMI 2") ha sostituito l'impresa comune IMI nel giugno 2014 allo scopo di completare le attività di ricerca nell'ambito del settimo programma quadro e ha prorogato la durata dell'impresa comune fino a dicembre 2024. L'impresa comune IMI mira ad aumentare significativamente l'efficacia e l'efficienza del processo di sviluppo dei medicinali cosicché il settore farmaceutico, a lungo termine, produca medicinali innovativi più efficaci e più sicuri. A tal fine, promuove la collaborazione fra i principali attori impegnati nella ricerca in materia di assistenza sanitaria, fra cui le università, le industrie farmaceutiche e altre industrie, le piccole e le medie imprese (PMI), le associazioni dei pazienti e gli enti di regolamentazione nel campo dei medicinali. Il contributo massimo dell'UE all'impresa comune IMI è di 1 milione di euro, quello a favore dell'IMI 2, invece, ammonta a 1 638 000 000 euro.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0922"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124986.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Matt Carthy (GUE/NGL), </span></span>  <span class="italic">in writing. ‒ </span>The joint undertakings are European Commission initiatives. They were set up as public-private partnerships aimed at mobilising and pooling European, national and private efforts, including private industry capital, to develop activities in the field of the European research, science and technology.</p>
<p class="contents">This joint undertaking is aimed at improving the efficiency and effectiveness of the drug development process for the production of safer innovative medicines.</p>
<p class="contents">While the accounts gave a fair representation of the joint undertaking’s financial position, the ex-ante control performed by the joint undertaking’s Scientific Project Officers (SPO) did not clearly identify and comment upon the status of the project and its deliverables, and payment was made without an official listing of deliverables accepted by the SPO and without any reference to the assessment of deliverables by the SPO.</p>
<p class="contents">Therefore I voted in favour of discharge but abstained on the approval of accounts. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0923"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124971.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">James Carver (EFDD), </span></span>  <span class="italic">in writing. ‒ </span>UKIP voted against the discharge votes for multiple reasons. Primarily we are against the EU spending taxpayers’ money, therefore we do not consent to this money being spent. Second of all, the lack of transparency in these procedure is of real concern to us. Finally many of these discharge reports call for a motion for resolution which requires further EU engagement which we are principally against. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0925"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28122.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">David Casa (PPE), </span></span>  <span class="italic">in writing. ‒ </span>The report aims to close the accounts of the Innovative Medicines Initiative 2 Joint Undertaking in respect of the implementation of its budget for the year 2014, and I voted in favour. The accounts raised no major questions. I also welcome the increasing involvement of SMEs in its activities and greater transparency regarding the management of the conflict of interests. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0927"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125061.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Κώστας Χρυσόγονος (</span></span>  <span class="bold">GUE</span><span class="bold">/</span><span class="bold">NGL</span><span class="bold">), </span><span class="italic">γραπτώς. ‒ </span>Η έκθεση σχετικά με την απαλλαγή της Κοινής επιχείρησης Πρωτοβουλίας για καινοτόμα φάρμακα 2 ως προς την εκτέλεση του γενικού προϋπολογισμού της Ευρωπαϊκής Ένωσης για το οικονομικό έτος 2014 αποτελεί μια καθιερωμένη διαδικασία ως προς τις αποφάσεις που ελήφθησαν και τις κινήσεις που έγιναν σχετικά με τη διαχείριση του προϋπολογισμού. Καθώς δεν προέκυψαν ζητήματα ικανά να οδηγήσουν σε απόρριψη των χειρισμών που πραγματοποιήθηκαν, ψήφισα θετικά.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0928"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124772.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alberto Cirio (PPE), </span></span>  <span class="italic">per iscritto. ‒ </span>Anche questa relazione è chiara nell'esprimere come questa impresa comune abbia utilizzato le risorse economiche a essa attribuite nel massimo rispetto dei controlli interni e esterni istituiti per la verifica delle spese. Soddisfatto inoltre dell'ottimo livello di trasparenza riscontrato all'interno della documentazione è stato per me semplice esprimermi a favore.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0929"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124988.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Deirdre Clune (PPE), </span></span>  <span class="italic">in writing. ‒ </span>CLEAN SKY, FCH, IMI and ITER obtained a clean opinion on the legality and regularity of the transactions underlying the accounts.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0931"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lara Comi (PPE), </span></span>  <span class="italic">per iscritto. ‒ </span>Dopo un’attenta analisi delle osservazioni avanzate dalla Corte dei conti e dell'effettività ed efficacia del mandato dell'impresa comune nel garantire che il settore farmaceutico produca medicinali innovativi sicuri, ho deciso di votare favorevolmente alla procedura di discarico per l'esecuzione del bilancio per l'esercizio 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0932"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124968.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Therese Comodini Cachia (PPE), </span></span>  <span class="italic">in writing. ‒ </span>I note the recommendation to approve the closure of the accounts of the Innovative Medicines Initiative for the financial year 2014 and support it. Regretfully, there is somewhat a lack of information regarding in-kind and cash contributions, and I join the call to include in future reports specific provisions regarding the evaluation procedure and the level of in-kind and cash contributions that are set out separately for FP 7 and Horizon 2020.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0933"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124970.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miriam Dalli (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>The report approves the closure of the accounts of the Innovative Medicines Initiative 2 Joint Undertaking for the financial year 2014. I voted in favour of granting this discharge, given that significant progress has been made by this joint undertaking in improving the situation of this sector in the past years.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0935"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/35135.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Daniel Dalton (ECR), </span></span>  <span class="italic">in writing. ‒ </span>I voted to postpone discharge on this report today because the European Court of Auditors did not give the EU budget as a whole a positive statement of assurance. The level of error for the year 2014 was estimated to be 4.4%, which, although it is a slight improvement on 2013, is still too high. It is the job of Parliament to verify that the EU budget has been spent in accordance with the rules and in line with the principles of sound financial management, and unfortunately the Court of Auditors found that was not the case for the year 2014. We need more simplification of key areas of financial management in the EU budget and a stronger focus on tackling parts of the budget with a higher risk of problems.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1761-0125"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96958.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">William (The Earl of) Dartmouth (EFDD), </span></span>  <span class="italic">in writing. ‒ </span>UKIP voted against the discharge votes for multiple reasons. Primarily we are against the EU spending taxpayers’ money, therefore we do not consent to this money being spent. Second of all, the lack of transparency in these procedure is of real concern to us. Finally many of these discharge reports call for a motion for resolution which requires further EU engagement which we are principally against. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124714.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andor Deli (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. </p>
<p class="contents">Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A szakbizottsági szavazáson és a plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0952"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96826.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tamás Deutsch (PPE),</span></span>   <span class="italic">írásban</span><span class="bold">. –</span> Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A szakbizottsági szavazáson és a plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0960"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124750.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mireille D'Ornano (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Le rapport rappelle que cette entreprise commune a été établie en vue de poursuivre et prolonger l'activité de la précédente, intitulée "entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants". Ceci permet aux projets concernés par les investissements de voir leur horizon étendu à 2024. </p>
<p class="contents">Le budget de l'Entreprise commune a été porté de 1 milliard à 1,6 milliards dans le programme pluriannuel Horizon 2020. Le rapport souligne que la répartition des engagements n'est pas clairement indiquée dans le rapport de gestion. On ignore s'ils dépendent du nouveau programme ou de l'ancien, ce qui rend l'évaluation et l'audit de l'entreprise commune incertains. Bien qu'elle n'ait pas fourni de chiffres clairs à partir desquels évaluer son activité ou son efficacité, l'entreprise commune fait l'objet d'un rapport bienveillant et peu critique. Aussi, j'ai voté contre cette décharge.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0968"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124711.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Norbert Erdős (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. </p>
<p class="contents">Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A plenáris szavazáson a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0984"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124767.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Edouard Ferrand (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Vote contre: le rapport n'a pas fourni de chiffres clairs à partir desquels évaluer son activité ou son efficacité.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0992"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4465.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Raffaele Fitto (ECR), </span></span>  <span class="italic">per iscritto. ‒ </span>Ho votato contro la concessione del discarico di bilancio per l'impresa comune sui medicinali innovativi. Vi sono diverse criticità e una rilevante percentuale di errore, riscontrate anche dalla Corte europea dei Conti. Ritengo di fondamentale importanza impegnarsi su un terreno che renda le Agenzie europee meno costose, meno distanti dalla gente e più vicine alle esigenze e agli interessi dei cittadini europei. Per questo motivo, è necessario un rinvio del discarico. In un periodo di forte euroscetticismo occorre un diverso tipo di approccio all'investimento del denaro pubblico, che non alimenti ulteriormente il sentimento di sfiducia dei cittadini europei nei confronti delle istituzioni europee e di ciò che rappresentano.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0996"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124985.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luke Ming Flanagan (GUE/NGL), </span></span>  <span class="italic">in writing. ‒ </span>I abstained because I could not agree totally with the discharge.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1763-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23868.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Flašíková Beňová (S&amp;D), </span></span>  <span class="italic">písomne ‒ </span>Pri tomto konkrétnom hlasovaní ide o udelenie rozpočtového absolutória pre Spoločný podnik pre iniciatívu pre inovačné lieky 2.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1763-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125070.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Λάμπρος Φουντούλης (</span></span>  <span class="bold">NI</span><span class="bold">), </span><span class="italic">γραπτώς. ‒ </span>Καταψηφίζω την έκθεση σχετικά με την απαλλαγή όσον αφορά την εκτέλεση του προϋπολογισμού της Κοινής Επιχείρησης Πρωτοβουλία για καινοτόμα φάρμακα 2 (πρώην κοινή επιχείρηση για την υλοποίηση της κοινής τεχνολογικής πρωτοβουλίας για τα καινοτόμα φάρμακα) για το οικονομικό έτος 2014 επειδή, αν και σε γενικές γραμμές η εν λόγω κοινή επιχείρηση παρουσιάζει ικανοποιητικά αποτελέσματα, υπάρχει εντούτοις έλλειψη πληροφοριών όσον αφορά τις εισφορές σε χρήμα ή σε είδος.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1763-0750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124790.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Doru-Claudian Frunzulică (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>I backed this report as agreed in Committee, granting discharge to IMI.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28150.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kinga Gál (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. </p>
<p class="contents">Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A szakbizottsági szavazáson és a plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124815.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Arne Gericke (ECR), </span></span>  <span class="italic">schriftlich. ‒ </span>Ich habe aus grundsätzlichen Erwägungen gegen die Entlastung dieses „Gemeinsamen Unternehmens“ gestimmt. Deren Einrichtung an der Schnittstelle EU, Mitgliedstaaten und Industrie erscheint mir wenig transparent und schwer kontrollierbar. Das unterstütze ich nicht.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124807.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jens Gieseke (PPE), </span></span>  <span class="italic">schriftlich. ‒ </span>Die gemeinsamen Unternehmen der Union leisten einen wichtigen Beitrag für die wirtschaftliche Entwicklung, das Wirtschaftswachstum und die Schaffung von Arbeitsplätzen. Des Weiteren erreichen sie einen hohen Stellenwert an Entwicklung und Innovation innerhalb der Forschung und erzielen hilfreiche Forschungsergebnisse in den einzelnen Branchen, in denen sie tätig sind.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124965.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nathan Gill (EFDD), </span></span>  <span class="italic">in writing. ‒ </span>I voted against discharge on the grounds that I disapprove of the European Union, and consequently I disapprove of the expenditure in this area.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124864.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michela Giuffrida (S&amp;D), </span></span>  <span class="italic">per iscritto. ‒ </span>Ho votato a favore di questa relazione perché l'impresa comune per l'attuazione dell'iniziativa tecnologica congiunta sui medicinali innovativi ("impresa comune IMI") costituita nel dicembre 2007 ha come obiettivo quello di aumentare significativamente l'efficacia e l'efficienza del processo di sviluppo dei medicinali per fare in modo che il settore farmaceutico possa, nel lungo periodo, produrre medicinali innovativi più efficaci e più sicuri. È necessario però che ogni anno le istituzioni e gli organismi dell'UE producano una relazione sulla gestione finanziaria e di bilancio e che le informazioni fornite dall'impresa comune in tale relazione siano armonizzate e non incomplete per un maggiore trasparenza e un più efficace controllo. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1764-0937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/127330.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tania González Peñas (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span> Se ha votado a favor de la aprobación la gestión y del cierre de cuentas al no encontrarse irregularidades reseñables. Ahora bien, es preciso señalar, como en el caso restante de las Joint Undertakings, que mantenemos una posición crítica sobre las mismas en tanto que la participación público-privada supone una privatización de los rendimientos y una mercantilización de actividades de utilidad pública.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">András Gyürk (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0125"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96907.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Τάκης Χατζηγεωργίου (</span></span>  <span class="bold">GUE</span><span class="bold">/</span><span class="bold">NGL</span><span class="bold">), </span><span class="italic">γραπτώς. ‒ </span>Ψηφίσαμε υπέρ της υπό εξέταση έκθεσης για την απαλλαγή και το κλείσιμο των λογαριασμών που αφορούσε την Ευρωπαϊκή Επιτροπή και τους εκτελεστικούς οργανισμούς δεδομένου ότι τα συστήματα εποπτείας και ελέγχου που απαιτεί ο δημοσιονομικός κανονισμός και οι πράξεις που ελέγχθηκαν ήταν απαλλαγμένες από ουσιώδη σφάλματα νομιμότητας και κανονικότητας. Επιπρόσθετα, η έκθεση ενισχύθηκε με τροπολογίες της Ομάδας μας που άπτονταν της καλύτερης δημοκρατικής λογοδοσίας των οργανισμών ενώ παράλληλα εισήχθησαν επαρκή μέτρα για να αποφευχθεί ο επηρεασμός των οργανισμών από τα λόμπυ των μεγάλων επιχειρήσεων.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0140"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28116.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marian Harkin (ALDE), </span></span>  <span class="italic">in writing. ‒ </span>I supported this report, as did the majority of Members. IMI 2 was set up to finish the work carried out by IMI 1 with the aim of significantly improving the efficiency and effectiveness of the drug development process with the long-term aim that the pharmaceutical sector produces more effective and safer innovative medicines. This is a vital role, considering the difficulties many Member States are facing with access to affordable medicines. However, the funds by the joint undertaking are not utilised in a good enough manner. The rapporteur acknowledges this and calls for greater utilisation of appropriated funds. Likewise, the Court of Auditors report is based on too many general remarks, to the detriment of viable, specific ones. I am glad that the report calls for an audit with a sharper focus on the annual financial performance, on the implementation status of multi-annual projects and on the results and their implementation. Likewise, the report also rightly highlights the decrease in the overall implementation rate, which went from 99.5% in 2013 to 92.4% in 2014 for commitment appropriations and 97.5% for 2013 to 73.0% in 2014 for payment appropriations. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0156"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118658.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Brian Hayes (PPE), </span></span>  <span class="italic">in writing. ‒ </span>I supported this discharge as I had no problems with the report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0163"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124715.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">György Hölvényi (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A plenáris szavazáson a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0171"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96857.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Cătălin Sorin Ivan (S&amp;D), </span></span>  <span class="italic">în scris. ‒ </span>Comisia Europeană este responsabilă pentru executarea bugetului Uniunii Europene. Aceasta implică statele membre cărora Comisia le deleagă sarcini de punere în aplicare legate de o parte semnificativă a bugetului. În fiecare an, procedura de descărcare de gestiune asigură un control ex-post democratic la nivel politic, arătându-se astfel modul în care s-a utilizat bugetul anual al UE. </p>
<p class="contents">Am votat în favoarea acestui raport al descărcării generale de gestiune 2014 referitor la inițiativa tehnologică comună privind medicamentele inovatoare prin care se solicită o poziție mai vigilentă a Comisiei cu privire la descărcarea de gestiune, solicitând acesteia să controleze mai frecvent domeniile în care au fost alocați banii și care prezintă un risc ridicat de erori, să se concentreze pe controalele ex-ante, să colaboreze mai eficient cu statele membre pentru a corecta erorile înaintea declarării cheltuielilor și să introducă mai multă transparență și flexibilitate în ceea ce privește creditele neutilizate.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0173"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124754.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ivan Jakovčić (ALDE), </span></span>  <span class="italic">napisan. ‒ </span>Glasao sam za Izvješće o razrješnici za izvršenje proračuna Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 (bivšeg Zajedničkog poduzeća za provedbu zajedničke tehnološke inicijative za inovativne lijekove) za financijsku godinu 2014., jer se na temelju godišnjeg izvješća o radu primjećuje da su do kraja 2014. izvršena četiri <span class="italic">ex post</span> pregleda i revizije odabranih trgovačkih društava koja pripadaju navedenom poduzeću, te su dva dodatna pregleda i revizije bili u tijeku. </p>
<p class="contents">Tim se radnjama obuhvatilo dionike koji su pružili najveće doprinose u naravi projektima Zajedničkog poduzeća, čime je zajamčena široka pokrivenost programa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0175"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124939.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diane James (EFDD),</span></span>   <span class="italic">in writing</span><span class="bold">. –</span> UKIP voted against the discharge votes for multiple reasons. Primarily we are against the EU spending tax payers money therefore we do not consent to this money being spent. Second of all, the lack of transparency in these procedure is of real concern to us. Finally many of these discharge reports calls for a motion for resolution which requires further EU engagement which we are principally against.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0179"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit. ‒ </span>J’ai voté en faveur de ce rapport qui donne décharge au directeur exécutif de l'entreprise commune IMI sur l'exécution du budget pour l'exercice 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0183"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125024.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Barbara Kappel (ENF), </span></span>  <span class="italic">schriftlich. ‒ </span>Ich stimme für den Entschließungsantrag zur Entlastung von IMI. Der Berichterstatter legt klar die Situation dar und hat meiner Meinung nach die richtigen Vorschläge gemacht.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0185"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124962.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Afzal Khan (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>I voted in favour of granting discharge to the joint undertaking given that significant progress and improvements have been made in terms of the recoveries reached, preventive measures taken and action plans implemented.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0186"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124824.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bernd Kölmel (ECR), </span></span>  <span class="italic">schriftlich. ‒ </span>In einer Situation, in der reiche Staaten wie Deutschland ihre Rentensysteme mittel- und langfristig nicht mehr finanzieren werden können, sind rasante Reformschritte nötig. Statt wie Wolfgang Schäuble über die Erhöhung des Rentenalters nachzudenken, fordert ALFA eine detaillierte Überprüfung der Haushaltsausgaben, einschließlich des deutschen Beitrags in den EU-Haushalt.</p>
<p class="contents">ALFA setzt sich für einen effizienteren EU-Haushalt ein und wendet sich entschieden gegen die Verschwendung von Steuergeldern, die auf nationalstaatlicher ähnlich wie auf der EU-Ebene ein großes Problem ist. Eine solche Einstellung erwartet ALFA vom ganzen Europäischen Parlament, das die Entlastung zum EU-Budget erteilt.</p>
<p class="contents">Da die Entwürfe des Ausschusses für Haushaltskontrolle generell eine Reform des EU-Budgets nicht stark genug gefordert hatten, habe ich gegen die Entlastung bei den meisten EU-Haushaltslinien gestimmt. Dies betraf auch die Entlastung zum Gemeinsamen Unternehmen „Initiative Innovative Arzneimittel 2“ (IMI).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0187"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96829.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ádám Kósa (PPE), </span></span>  <span class="italic">írásban. ‒ </span>Az Európai Számvevőszék 2014-es pénzügyi évre vonatkozó éves jelentésének bemutatását követően a 2014. évi zárszámadási eljárás keretében az Európai Parlament Költségvetési Ellenőrző Bizottsága elvégezte az Európai Unió általános költségvetésének az Innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozásra vonatkozó pénzügyi ellenőrzését. A Számvevőszék kijelentette, hogy kellő mértékben megbizonyosodott arról, hogy az intézet éves beszámolója megbízható, és a beszámolókban foglalt ügyleteket jogszerűnek és szabályszerűnek ítélte. </p>
<p class="contents">Az előző pénzügyi évhez képest jelentős előrelépést sikerült elérnie a közös vállalkozásnak és egy olyan cselekvési tervet sikerült véghezvinnie, amely világos és konkrét eredményeket hozott az összeférhetetlenségek megelőzése és az átláthatóság megerősítése vonatkozásában. A szakbizottság április eleji ülésén a mentesítés megadásáról döntött. A szakbizottsági szavazáson és a plenáris szavazáson is a mentesítés megadását támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0194"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via (PPE), </span></span>  <span class="italic">per iscritto. ‒ </span>La proposta di risoluzione del Parlamento europeo in materia di discarico dell'impresa comune per l'iniziativa in materia di medicinali innovativi 2 (IMI), analizza attentamente la relazione della Corte dei conti in materia di gestione finanziaria e di bilancio, inviti a presentare proposte, conflitti di interesse, quadro giuridico, e sistemi di controllo interno. Si prende atto del giudizio emesso dalla Corte dei conti in tema di legittimità e regolarità delle operazioni, in merito ai conti annuali dell´impresa comune per l'esercizio 2014, riconoscendo che la stessa impresa ha rispettato la soglia di rilevanza. Si invita, al contempo, l'impresa comune a intraprendere una adeguata attività di informazione sulle attività da essa compiute e a rendere il procedimento più trasparente possibile. Alla luce delle suesposte ragioni, voto favorevolmente la relazione sulla concessione del discarico.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0202"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28210.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marine Le Pen (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai voté contre l'octroi de la décharge à l'entreprise commune "Initiative en matière de médicaments innovants 2" (IMI). Les membres fondateurs de cette initiative sont l'UE, représentée par la Commission, et la fédération des entreprises européennes pharmaceutiques. Le budget de l'Entreprise commune a été porté de 1 milliard à 1,6 milliard dans le programme pluriannuel Horizon 2020. Le rapport souligne que la répartition des engagements n'est pas clairement indiquée dans le rapport de gestion: dépendent-ils du nouveau programme ou de l'ancien (le 7e programme pluriannuel). Ceci rend l'évaluation et l'audit de l'entreprise commune incertains. </p>
<p class="contents">Alors qu'elle n'a pas fourni de chiffres clairs à partir desquels évaluer son activité ou son efficacité, l'entreprise commune fait l'objet d'un rapport bienveillant et peu critique. Je ne peux que le regretter.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0203"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124738.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Lebreton (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>J’ai voté contre ce rapport qui appelle à octroyer la décharge sur l'exécution du budget.</p>
<p class="contents">Le rapport souligne que la répartition des engagements n'est pas clairement indiquée dans le rapport de gestion. Nous ne savons pas s’ils dépendent du nouveau programme ou de l'ancien (le 7e programme pluriannuel). Ceci rend l'évaluation et l'audit de l'entreprise commune incertains. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0001"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125684.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Loiseau (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Il apparaît clairement que le présent texte se veut bienveillant, ce qui empêche d'avoir une analyse constructive de l'utilisation du budget 2014 pour l'entreprise commune "Initiative en matière de médicaments innovants 2". Fruit d'une volonté politique conjointe de l'Union (représentée par la Commission) et de la Fédération des entreprises européennes pharmaceutiques, cette institution veut être à l'avant-garde de l'innovation biopharmaceutique. Elle se voit allouer des fonds importants qui lui permettent d'investir dans des projets jusqu'en 2024. </p>
<p class="contents">Néanmoins, le respect de cet objectif ne pourra se faire qu'avec l'apport de précisions concernant la répartition des engagements, des chiffres clairs... Il est évident que le rapporteur n'a pas soulevé les problèmes fondamentaux, ce qui fausse l'analyse. Je rejette donc la proposition de lui accorder la décharge pour 2014. J'ai logiquement voté contre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0204"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124820.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bernd Lucke (ECR), </span></span>  <span class="italic">schriftlich. ‒ </span>In einer Situation, in der reiche Staaten wie Deutschland ihre Rentensysteme mittel- und langfristig nicht mehr finanzieren werden können, sind deutliche Reformschritte nötig. Statt wie Wolfgang Schäuble über die Erhöhung des Rentenalters nachzudenken, fordert ALFA eine detaillierte Überprüfung der Haushaltsausgaben, einschließlich des deutschen Beitrags in den EU-Haushalt.</p>
<p class="contents">ALFA setzt sich für einen effizienteren EU-Haushalt ein und wendet sich entschieden gegen die Verschwendung von Steuergeldern, die auf nationalstaatlicher ähnlich wie auf der EU-Ebene ein großes Problem ist. Eine solche Einstellung erwartet ALFA von dem ganzen Europaparlament, das die Entlastung zum EU-Budget erteilt.</p>
<p class="contents">Da die Entwürfe des Ausschusses für Haushaltskontrolle generell eine Reform des EU-Budgets nicht deutlich genug gefordert hatten, habe ich gegen die Entlastung bei den meisten EU-Haushaltslinien gestimmt. Dies betraf auch die Entlastung zum Gemeinsamen Unternehmen „Initiative Innovative Arzneimittel 2“ (IMI).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0206"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119436.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ivana Maletić (PPE), </span></span>  <span class="italic">napisan. ‒ </span>U izvješću Revizorskog suda za financijsku godinu 2014. utvrđeno je kako je godišnja računovodstvena dokumentacija u uskladu s financijskim i računovodstvenim pravilima. Temeljem izvješća Revizorskog suda, podržala sam Izvješće o davanju razrješnice izvršnom direktoru Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za izvršenje proračuna za 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0603"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124746.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andrejs Mamikins (S&amp;D), </span></span>  <span class="italic">rakstiski. ‒ </span>Kopuzņēmuma "2. ierosme inovatīvu zāļu jomā" uzdevums ir veicināt zāļu izstrādi, sekmējot atklātu sadarbību pētniecībā, kas potenciāli spēj paātrināt nepieciešamo zāļu izveidi. Šajā visai svarīgajā darbā tiek apvienotas augstskolas, farmācijas nozare un citas nozares, mazie un vidējie uzņēmumi, pacientu organizācijas un zāles reglamentējošās iestādes.</p>
<p class="contents">Savienības maksimālais ieguldījums <span class="italic">IMI</span> darbības laikā varēs sastādīt 1 miljardu euro, savukārt <span class="italic">IMI2</span> (kas aizstāja pirmo 2014. gadā) — 1,638 miljardu euro. <span class="italic">IMI2</span> gadījumā pārējiem dalībniekiem (neieskaitot Komisiju) jāsedz 50 % no saimnieciskajiem izdevumiem un jāpiedalās darbības izdevumu segšanā ar skaidru naudu vai natūrā.</p>
<p class="contents">Pievienojos tā fakta atzinīgai vērtēšanai, ka 2016. gada februārī tika publicēta īsa analīze par Kopuzņēmuma projektu tiešajiem rezultātiem saistībā ar sociālekonomisko ietekmi.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0801"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125069.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νότης Μαριάς (</span></span>  <span class="bold">ECR</span><span class="bold">), </span><span class="italic">γραπτώς. ‒ </span>Για λόγους έλλειψης: α) πλήρους διαφάνειας, β) σοβαρής τεκμηρίωσης, γ) αξιοπιστίας, δ) επαρκών στοιχείων αναφορικά με την εκτέλεση του υπό ψήφιση προϋπολογισμού της οικείας κοινής τεχνολογικής πρωτοβουλίας καταψηφίζω την έκθεση σχετικά με την απαλλαγή όσον αφορά την εκτέλεση του προϋπολογισμού της Κοινής Επιχείρησης Πρωτοβουλία για καινοτόμα φάρμακα 2 (πρώην κοινή επιχείρηση για την υλοποίηση της κοινής τεχνολογικής πρωτοβουλίας για τα καινοτόμα φάρμακα) για το οικονομικό έτος 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0900"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124751.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dominique Martin (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai voté contre ce texte.</p>
<p class="contents">Le budget de l'entreprise commune a été porté de 1 milliard à 1,6 milliard dans le programme pluriannuel Horizon 2020. Le rapport souligne que la répartition des engagements n'est pas clairement indiquée dans le rapport de gestion et bien qu'elle n'ait pas fourni de chiffres clairs à partir desquels évaluer son activité ou son efficacité, l'entreprise commune fait l'objet d'un rapport bienveillant et peu critique.</p>
<p class="contents">Nous ne pouvons que le regretter.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0926"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124812.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Fabio Massimo Castaldo (EFDD), </span></span>  <span class="italic">per iscritto. ‒ </span>Ho votato a favore della risoluzione in quanto mette in luce, in modo rigoroso e sistematico, le problematiche specifiche dell'IMI.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1762-0963"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/26837.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Λευτέρης Χριστοφόρου (PPE), </span></span>  <span class="italic">γραπτώς. ‒ </span>Στηρίζουμε την έκθεση, η οποία θεωρούμε πως δικαιολογημένα χορηγεί απαλλαγή στον εκτελεστικό διευθυντή της κοινής επιχείρησης της πρωτοβουλίας για τα καινοτόμα φάρμακα 2 (πρώην κοινή επιχείρηση για την υλοποίηση της κοινής τεχνολογικής πρωτοβουλίας για τα καινοτόμα φάρμακα) όσον αφορά την εκτέλεση του προϋπολογισμού της κοινής επιχείρησης για το οικονομικό έτος 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0210"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96820.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marisa Matias (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>Apesar de não estar de acordo e questionar tantas vezes as atividades desenvolvidas pela Empresa Comum Iniciativa sobre Medicamentos Inovadores 2, optei pela abstenção por entender que não se podem pôr em causa os salários e demais direitos dos trabalhadores.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0218"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit. ‒ </span>Ce rapport propose de donner quitus pour l'exécution du budget 2014 de l'Entreprise commune "Initiative en matière de médicaments innovants 2" (IMI). Je m'étais opposé au cadre général de ce budget lors de son vote en 2013. Les points sur lesquels j'avais alors alerté se sont tous vérifié. Et les engagements intenables pris alors par les institutions européennes n'ont pas été tenus. </p>
<p class="contents">2014 devait en particulier être l'année de la résorption finale de tous les impayés de l’UE, dont certains s'accumulent depuis 9 ans. Une tâche impossible avec un budget en baisse de 6 % (moins 10 milliards), même en consacrant plus de la moitié des crédits de paiements de l'année 2014 à payer des engagements pris les années précédentes. Résultat: les impayés sont toujours là (estimés à 2 milliards fin 2016) et les besoins budgétaires d'avenir ne sont pas couverts. Je confirme mon opposition à ce cadre budgétaire d'austérité en votant contre cette décharge.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0220"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124765.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Joëlle Mélin (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Les chiffres de l'activité de l'entreprise restent assez obscurs. Le rapport n'en tire aucune conséquence. Aussi ai-je voté contre. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0222"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito. ‒ </span>Todas as instituições europeias que dependem do orçamento da União Europeia têm que ser fiscalizadas de forma rigorosa.</p>
<p class="contents">É necessário aferir se os fundos comunitários estão a ser bem utilizados, se essas instituições estão a cumprir com os objetivos delineados e se não existe desperdício de recursos.</p>
<p class="contents">De um modo geral, salvo raras exceções, a avaliar pelas fiscalizações conhecidas, podemos afirmar que as instituições em causa estão a utilizar de forma correta os fundos disponibilizados e a cumprir com os objetivos propostos.</p>
<p class="contents">Votei favoravelmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0224"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing. ‒ </span>Following the recommendation from the Council, the declaration of assurance from the Court of Auditors and the report from the Committee of Budgetary Control, I chose to support the decision regarding the discharge on the implementation of the budget of the Innovative Medicines Initiative 2 Joint Undertaking for the financial year 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0226"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96670.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Louis Michel (ALDE),</span></span>   <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de la décharge sur l'exécution du budget de l'entreprise commune "Initiative en matière de médicaments innovants 2" pour l'exercice 2014. L'entreprise commune, constituée en décembre 2007, a pour objectif d'améliorer l'efficience et l'efficacité du processus de mise au point des médicaments afin qu'à long terme le secteur pharmaceutique produise des médicaments innovants plus sûrs et plus efficaces.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0234"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>I voted in favour of granting discharge in respect of the implementation of the budget of the Innovative Medicines Initiative 2 Joint Undertaking for the financial year 2014, because the final accounts of the Innovative Medicines Initiative 2 Joint Undertaking for the financial year 2014 are as annexed to the Court of Auditors’ report and because I agree with the closure of the accounts of the agency for the financial year 2014. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0236"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124722.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Csaba Molnár (S&amp;D), </span></span>  <span class="italic">írásban. ‒ </span>Az innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító második közös vállalkozás benyújtotta a 2014-es pénzügyi évre vonatkozó végleges éves beszámolóját. A Tanács, a Számvevőszéknek az éves beszámolóról szóló jelentése alapján 2016. február 12-én ajánlást tett a Parlamentnek, hogy a közös vállalkozás ügyvezető igazgatóját mentesítse az IMI 2014-es pénzügyi évre szóló költségvetése végrehajtására vonatkozó felelősség alól. A Költségvetési Ellenőrző Bizottság jelentésében azt javasolta, hogy a Parlament ezt a mentesítést adja meg. Ennek megfelelően szavaztam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0238"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124734.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Cláudia Monteiro de Aguiar (PPE), </span></span>  <span class="italic">por escrito. ‒ </span>Pelo exposto no presente relatório, o mesmo merece o meu voto favorável, no sentido de dar quitação ao Diretor Executivo da Empresa Comum «Iniciativa sobre Medicamentos Inovadores 2» (Empresa Comum para a execução da iniciativa tecnológica conjunta sobre medicamentos inovadores) pela execução do orçamento da Empresa Comum para o exercício de 2014.</p>
<p class="contents">Defendo que as observações/sugestões apresentadas devem ser tidas em consideração futuramente. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0242"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124769.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sophie Montel (ENF), </span></span>  <span class="italic">par écrit. ‒ </span>Au vu des problèmes évoqués, le ton du rapport est clairement insuffisamment critique. Je vote contre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72779.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nadine Morano (PPE), </span></span>  <span class="italic">par écrit. ‒ </span>Il s'agissait dans ce rapport de se prononcer sur la décharge budgétaire 2014 pour l'initiative en matière de médicaments innovants 2 qui a été constituée en décembre 2007 pour une période de dix ans en vue d'améliorer sensiblement l'efficience et l'efficacité du processus de mise au point des médicaments et dans le but, à plus long terme, que le secteur pharmaceutique produise des médicaments innovants plus efficaces et plus sûrs.</p>
<p class="contents">La décharge budgétaire, qui peut être accordée, ajournée ou refusée par le Parlement européen, constitue le contrôle final du budget annuel. Le processus de décharge représente le volet politique du contrôle de l'exécution budgétaire.</p>
<p class="contents">Dans le cas de l'IMI 2, le rapport pointe le manque d'informations précises présentes dans les audits réalisés par la cour des comptes. Cependant, au vu notamment des bons taux d’exécution du budget (92,4 pour les crédits d'engagement et 73,9 pour les crédits de paiement), notamment pour les activités opérationnelles, la cour des comptes est en mesure d'estimer qu'elle a reçu les assurances nécessaires sur la légalité et la régularité des comptes et des opérations financières pour l’exercice 2014. J'ai donc voté en faveur de l'octroi de la décharge. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0312"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124729.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Renaud Muselier (PPE), </span></span>  <span class="italic">par écrit. ‒ </span>La Cour des comptes ayant donné une opinion positive sur la fiabilité des comptes et sur la fiabilité et la régularité des transactions sous-jacentes, j'ai voté en faveur de la décharge. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0343"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/88882.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Victor Negrescu (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>Ultimately, the European Commission is responsible for the execution of the European Union’s budget. The decision as to whether to grant discharge for the execution of the EU budget is made by the European Parliament. The discharge procedure ensures ex-post democratic oversight at political level of how the EU’s annual budget has been used. It aim is to verify that the implementation was in accordance with relevant rules and principles of sound financial management. The report underlines that the use of EU funding must be efficient in advancing EU goals, the project should be aligned with the EU policies and better synergy should be achieved between all available resources in the fields, such as neighbourhood policy, external aid, and tackling the youth unemployment. </p>
<p class="contents">I have voted for this report on Innovative Medicines Initiative 2 Joint Undertaking (IMI) discharge, which calls for a more vigilant position on the discharge, asking the Commission to control more frequently areas and recipients with high risk of errors, focus on ex-ante controls, collaborate with the member states to correct errors before declaring expenditure and introduce more transparency and flexibility in spending so that unused appropriations can be used for new priorities.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0359"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124784.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dan Nica (S&amp;D), </span></span>  <span class="italic">în scris. ‒ </span>Am votat descărcarea de gestiune pentru execuția bugetului întreprinderii comune referitoare la inițiativa privind medicamentele inovatoare 2 (IMI2) aferent exercițiului financiar 2014.</p>
<p class="contents">Întreprinderea comună IMI 2 a înlocuit întreprinderea comună IMI în mai 2014, cu scopul de a finaliza activitățile de cercetare ale celui de-al șaptelea program-cadru și a prelungit durata de existență a întreprinderii comune până la data de 31 decembrie 2024. Contribuția maximă a Uniunii la întreprinderea comună IMI pentru perioada de 10 ani este de 1 miliard de EUR, sumă care provine din bugetul PC7, iar membrii fondatori trebuie să contribuie în mod egal la costurile de funcționare, fiecare cu o sumă care să nu depășească 4 % din contribuția totală a Uniunii.</p>
<p class="contents">Salutăm faptul că cererile de propuneri organizate în cadrul PC7 pentru perioada 2008-2013 au dus la semnarea a 54 de acorduri de grant în valoare totală de 897 000 000 EUR, ceea ce reprezintă 93% din contribuția maximă acordată de UE întreprinderii comune pentru activitățile sale de cercetare.</p>
<p class="contents">Solicităm Curții să includă în viitoarele sale rapoarte dispoziții specifice referitoare la procedura de evaluare și la nivelul de contribuții în natură și în numerar, prezentându-le pentru PC 7 separat de cele pentru Orizont 2020.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0367"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124987.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Liadh Ní Riada (GUE/NGL),</span></span>   <span class="italic">in writing</span><span class="bold">. </span>– This joint undertaking (JU) is aimed at improving the efficiency and effectiveness of the drug development process for the production of safer innovative medicines. While the accounts gave a fair representation of the joint undertaking’s financial position, the ex-ante control performed by the joint undertaking’s Scientific Project Officers (SPO) did not clearly identify and comment upon the status of the project and its deliverables, and payment was made without an official listing of deliverables accepted by the SPO and without any reference to the assessment of deliverables by the SPO. Therefore I voted in favour of discharge but abstained on the approval of accounts.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96981.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Franz Obermayr (ENF), </span></span>  <span class="italic">schriftlich. ‒ </span>Ich habe mich für diese Entschließung ausgesprochen, da der Bericht einige kritische Punkte enthält, und mache auf mangelnde Transparenz in den Prozessen und auf fehlende Kontrollen aufmerksam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0437"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/129073.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Urmas Paet (ALDE), </span></span>  <span class="italic">kirjalikult. ‒ </span>Toetasin. Tegemist on eelarve täitmise heakskiitmisega.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36392.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Aldo Patriciello (PPE), </span></span>  <span class="italic">per iscritto. ‒ </span>In linea con le osservazioni della Corte dei conti in merito all'analisi dei conti annuali dell'impresa comune in questione, ho votato a favore della proposta del collega.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124749.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marijana Petir (PPE), </span></span>  <span class="italic">napisan. </span><span class="italic">‒ </span>Zajedničko poduzeće za inicijativu za inovativne lijekove osnovano je u prosincu 2007. godine na razdoblje u trajanju od 10 godina kako bi se znatno poboljšala učinkovitost i djelotvornost postupka razvoja lijekova. Dugoročni cilj poduzeća je da pomogne farmaceutskom sektoru u razvoju i proizvodnji učinkovitijih i sigurnijih inovativnih lijekova. Financijsko izvješće pokazuje da je godišnji proračun Zajedničkog poduzeća za inicijativu za inovativne lijekove za 2014. uključivao 223 000 000 EUR odobrenih sredstava te 171 000 000 EUR sredstava za plaćanja. </p>
<p class="contents">Revizorski sud je u svojem izvješću o godišnjoj računovodstvenoj dokumentaciji Zajedničkog poduzeća za inicijativu za inovativne lijekove za financijsku godinu 2014. naveo kako je stekao razumno uvjerenje da je godišnja računovodstvena dokumentacija Zajedničkog poduzeća za inicijativu za inovativne lijekove za financijsku 2014. godinu pouzdana te da su povezane transakcije zakonite i pravilne. Podržala sam, stoga, razrješnicu za izvršenje proračuna Zajedničkog poduzeća za inicijativu za inovativne lijekove za financijsku 2014. godinu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112744.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tonino Picula (S&amp;D), </span></span>  <span class="italic">napisan. ‒ </span>Europski parlament je, uzimajući u obzir završne godišnje financijske izvještaje Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za financijsku godinu 2014., te uzimajući u obzir izvješće Odbora za proračunski nadzor, dao razrješnicu izvršnom direktoru Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 (bivšeg Zajedničkog poduzeća za provedbu zajedničke tehnološke inicijative za inovativne lijekove) za izvršenje proračuna Zajedničkog poduzeća za financijsku godinu 2014.</p>
<p class="contents">Odobrio je i zaključenje poslovnih knjiga Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za 2014. godinu. Primjećujem da se izvješće Revizorskog suda temeljilo na previše općenitim primjedbi umjesto na utemeljenim i konkretnim primjedbama. </p>
<p class="contents">Slijedom svega navedenog, pozdravljam Odluku o razrješnici za izvršenje proračuna Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 (bivšeg Zajedničkog poduzeća za provedbu zajedničke tehnološke inicijative za inovativne lijekove) za financijsku godinu 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0781"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124699.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Poche (S&amp;D), </span></span>  <span class="italic">písemně. ‒ </span>Jako stínový zpravodaj pro tuto zprávu jsem podpořil udělení rozpočtového absolutoria podniku IMI. Nenalezl jsem žádný závažný důvod pro neudělení a naopak bych se chtěl alespoň touto cestou ohradit proti kritickému jazyku použitému zpravodajem proti Evropskému účetnímu dvoru. EÚD si mimořádně vážím pro jeho velmi kvalitní práci a vynikající komunikaci. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0796"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/106202.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Julia Reid (EFDD), </span></span>  <span class="italic">in writing. ‒ </span>UKIP voted against the discharge votes for multiple reasons. Primarily we are against the EU spending taxpayers’ money, therefore we do not consent to this money being spent. Second of all, the lack of transparency in these procedure is of real concern to us. Finally many of these discharge reports call for a motion for resolution which requires further EU engagement which we are principally against.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0812"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4253.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Frédérique Ries (ALDE), </span></span>  <span class="italic">par écrit. ‒ </span>Ce vote approuve la décharge 2014 des comptes de l'entreprise commune "Initiative en matière de médicaments innovants 2" (IMI2), une initiative technologique communautaire pour combler le fossé existant entre l'Europe et ses concurrents en la matière.</p>
<p class="contents">Fondée en 2007 comme un partenariat public-privé entre l'UE et la Fédération européenne des associations de l’industrie pharmaceutique, IMI2 coordonne plus d'une dizaine de projets pour mieux comprendre certains problèmes de santé - tels que le diabète, la douleur, et les troubles psychiatriques - et contribue à renforcer la sécurité des médicaments. Elle améliore également la formation des chercheurs et des cliniciens qui participent à la mise au point de médicaments. </p>
<p class="contents">Lors de ce rituel annuel de la décharge européenne, le Parlement s'est livré à la vérification des comptes d'IMI2 au même titre que de ceux de près de 50 autres agences et instituts européens. Tout en admettant la bonne gestion des fonds alloués, et en félicitant IMI2 pour la volonté de transparence qu'elle affiche en matière de conflit d'intérêt pour ses conseils scientifique et de direction, le Parlement l'a encouragé à être plus précise sur l'état d'avancement de ses projets et dans la planification de ses activités à venir.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0819"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125107.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claude Rolin (PPE), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai voté en faveur de cette décharge budgétaire qui, sur la base du rapport de la Cour des comptes sur les comptes annuels de l'entreprise commune pour l'initiative en matière de médicaments innovants relatifs à l'exercice 2014, au vu de la déclaration d'assurance relative à la fiabilité des comptes ainsi que la légalité et la régularité des opérations sous-jacentes, fournie par la Cour des comptes et sur la base du rapport de la commission du contrôle budgétaire, vient donner décharge au directeur exécutif de l'entreprise commune "Initiative en matière de médicaments innovants 2" (anciennement l'entreprise commune pour la mise en œuvre de l'initiative technologique conjointe en matière de médicaments innovants) sur l'exécution du budget de l'entreprise commune pour l'exercice 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0823"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125214.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bronis Ropė (Verts/ALE), </span></span>  <span class="italic">raštu. ‒ </span>Balsavau už šį pranešimą, kuriuo tvirtinamas 2014 finansinių metų II naujoviškų vaistų iniciatyvos bendrosios įmonės biudžeto įvykdymas. Bendrosios įmonės 2014 m. biudžete buvo numatyta 223 000 000 EUR įsipareigojimų asignavimų suma ir 171 000 000 EUR mokėjimų asignavimų suma. Bendras įsipareigojimų asignavimų įgyvendinimo lygis buvo 92,4 proc., tuo tarpu 2013 m – 99,5 proc., o mokėjimų asignavimų – 73,9 proc., kai 2013 m. – 97,5 proc.</p>
<p class="contents">Nepaisant duomenų apie įmonę ribotumo, džiugu, kad Įmonė deda pastangas siekdama išvengti interesų konfliktų. Štai jos interneto svetainėje viešai paskelbta Bendrosios įmonės vykdomojo direktoriaus ir darbuotojų interesų deklaracijos, valdybos ir mokslinio komiteto narių gyvenimo aprašymai ir valstybių atstovų grupės narių pavardės. Įmonė taip pat stengiasi tobulinti savo veiklą – ji atsižvelgė į visas Komisijos Vidaus audito tarnybos atlikto veiklos rezultatų ir ataskaitų teikimo audito rekomendacijas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0825"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125035.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lola Sánchez Caldentey (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span> Se ha votado a favor de la aprobación la gestión y del cierre de cuentas al no encontrarse irregularidades reseñables. Ahora bien, es preciso señalar, como en el caso restante de las Joint Undertakings, que mantenemos una posición crítica sobre las mismas en tanto que la participación público-privada supone una privatización de los rendimientos y una mercantilización de actividades de utilidad pública.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0827"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125049.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria Lidia Senra Rodríguez (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>IMI es una Empresa Común dedica a la innovación médica. Debido a la vaguedad con la que se nos presenta su contabilidad y el hecho que la UE ha adoptado un modelo de innovación médica que privilegia los ingresos de las farmacéuticas frente a la salud pública, he decidido votar en contra de la decisión presupuestaria, votando a favor de la resolución final.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0835"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Siôn Simon (S&amp;D), </span></span>  <span class="italic">in writing. ‒ </span>The Innovative Medicines Initiative 2 Joint Undertaking brings together industry and research bodies in public and private partnerships to support research, new technology and demonstration activities and to accelerate the market introduction of specific technologies. I’m supporting this discharge for these reasons and I look forward to seeing what comes out of this one in particular, as its work has much life-changing potential for my constituents.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0839"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124927.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Branislav Škripek (ECR), </span></span>  <span class="italic">písomne ‒ </span>Hlasoval som proti udeleniu absolutória za plnenie rozpočtu spoločného podniku pre iniciatívu pre inovačné lieky 2. Som presvedčený, že rozpočet EÚ ako celok má získať najprv kladné stanovisko od Dvora audítorov.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0841"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124756.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Davor Škrlec (Verts/ALE), </span></span>  <span class="italic">napisan. ‒ </span>Podržao sam ovu razrješnicu, no ovo obrazloženje glasovanja nastaje kao kritika postojećem sustavu vrednovanja rada zastupnika u Europskom parlamentu isključivo na osnovu statističkog broja parlamentarnih aktivnosti potenciranog u Hrvatskoj, a koji zapravo ne odražava stvarnu kvalitetu i količinu rada, učinkovitost te ponajviše uspjeh zastupničkog djelovanja.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0842"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125003.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Igor Šoltes (Verts/ALE), </span></span>  <span class="italic">pisno. ‒ </span>V okviru vsakoletnega proračunskega postopka, ki ob številnih pogajanjih in usklajevanjih lahko traja tudi do sedem mesecev, tri temeljne institucije EU sprejmejo evropski proračun za prihodnje leto. Za njegovo izvajanje so nato zadolžene Evropska komisija in druge institucije. Evropski parlament kot neposredno izvoljena institucija, ki zastopa davkoplačevalce EU, izvaja demokratični nadzor ter skrbi, da Komisija in druge institucije ustrezno ravnajo z evropskimi sredstvi.</p>
<p class="contents">Parlament v svojem letnem postopku razrešnice sklene, ali bo podelil razrešnico in dokončno odobril način, na katerega se je v posameznem letu izvrševal proračun. Parlament pred odločitvijo preuči priporočila Odbora za proračunski nadzor in pri tem upošteva tudi letno poročilo Računskega sodišča ter odgovore Komisije na poslanska vprašanja.</p>
<p class="contents">Poročilo poročevalca kolega Marinesca navaja utemeljene razloge v prid podelitvi razrešnice Skupnemu podjetju za pobudo za inovativna zdravila, zato sem ga pri glasovanju podprl.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0002"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124827.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Joachim Starbatty (ECR), </span></span>  <span class="italic">schriftlich. ‒ </span>In einer Situation, in der reiche Staaten wie Deutschland ihre Rentensysteme mittel- und langfristig nicht mehr finanzieren werden können, sind deutliche Reformschritte nötig. Statt wie Wolfgang Schäuble über die Erhöhung des Rentenalters nachzudenken, fordert ALFA eine detaillierte Überprüfung der Haushaltsausgaben, einschließlich des deutschen Beitrags in den EU-Haushalt.</p>
<p class="contents">ALFA setzt sich für einen effizienteren EU-Haushalt ein und wendet sich entschieden gegen die Verschwendung von Steuergeldern, die auf nationalstaatlicher ähnlich wie auf der EU-Ebene ein großes Problem ist. Eine solche Einstellung erwartet ALFA von dem ganzen Europaparlament, das die Entlastung zum EU-Budget erteilt.</p>
<p class="contents">Da die Entwürfe des Ausschusses für Haushaltskontrolle generell eine Reform des EU-Budgets nicht deutlich genug gefordert hatten, habe ich gegen die Entlastung bei den meisten EU-Haushaltslinien gestimmt. Dies betraf auch die Entlastung zum Gemeinsamen Unternehmen „Initiative Innovative Arzneimittel 2“ (IMI).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0422"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124929.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ivan Štefanec (PPE), </span></span>  <span class="italic">písomne ‒ </span>Európsky parlament udelil spoločnému podniku pre iniciatívu pre inovačné lieky 2 absolutórium za plnenie rozpočtu podniku za rozpočtový rok 2014 a zároveň schválil účtovnú závierku. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0843"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119435.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Davor Ivo Stier (PPE), </span></span>  <span class="italic">napisan. ‒ </span>Zajedničko poduzeće za provedbu zajedničke tehnološke inicijative za inovativne lijekove je osnovano u prosincu 2007. na razdoblje od 10 godina kako bi se znatno poboljšala učinkovitost i djelotvornost postupka razvoja lijekova s dugoročnim ciljem da farmaceutski sektor proizvodi učinkovitije i sigurnije inovativne lijekove. Rezultati operativnih <span class="italic">ex ante</span> kontrola plaćanja projektnih troškova nisu bili zadovoljavajuće dokumentirani na način da se nije jasno naznačila niti objasnila faza projekta kao ni sve što je njime ostvareno. </p>
<p class="contents">Međutim, također pozitivno je što uključenost malih i srednjih poduzeća neprestano raste zahvaljujući promicanju njihova sudjelovanja u aktivnostima Zajedničkog poduzeća. Stoga, podržavam razrješnicu izvršnom direktoru Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za izvršenje proračuna Zajedničkog poduzeća za financijsku godinu 2014. te zaključenje poslovnih knjiga Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za financijsku godinu 2014.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119434.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dubravka Šuica (PPE), </span></span>  <span class="italic">napisan. ‒ </span>Zajedničko poduzeće za provedbu zajedničke tehnološke inicijative za inovativne lijekove je osnovano u prosincu 2007. na razdoblje od 10 godina kako bi se znatno poboljšala učinkovitost i djelotvornost postupka razvoja lijekova s dugoročnim ciljem da farmaceutski sektor proizvodi učinkovitije i sigurnije inovativne lijekove. Europski parlament primjećuje da rezultati operativnih <span class="italic">ex ante</span> kontrola plaćanja projektnih troškova nisu bili zadovoljavajuće dokumentirani na način da se nije jasno naznačila niti objasnila faza projekta kao ni sve što je njime ostvareno. </p>
<p class="contents">Međutim, također primjećuje da je pozitivna stvar što uključenost malih i srednjih poduzeća neprestano raste zahvaljujući promicanju njihova sudjelovanja u aktivnostima Zajedničkog poduzeća. Europski parlament u svom izvješću stoga daje razrješnicu izvršnom direktoru Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za izvršenje proračuna Zajedničkog poduzeća za financijsku godinu 2014. te odobrava zaključenje poslovnih knjiga Zajedničkog poduzeća za inicijativu za inovativne lijekove 2 za financijsku godinu 2014. Ovo izvješće podržavam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1765-0937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124703.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tibor Szanyi (S&amp;D), </span></span>  <span class="italic">írásban. ‒ </span>Az innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozást 2007 decemberében hozták létre 10 éves időszakra annak érdekében, hogy jelentősen javuljon a gyógyszerfejlesztés folyamatának hatékonysága és eredményessége, azzal a hosszú távú céllal, hogy a gyógyszeripari ágazat hatékonyabb és biztonságosabb innovatív gyógyszereket gyártson. A jelentés megállapítja, hogy a Számvevőszék jelentése túl sok általános észrevételen alapul gyakorlati, konkrét észrevételek helyett. Éppen ezért kéri, hogy végezzenek el egy olyan ellenőrzést, amely jobban összpontosít az éves pénzügyi teljesítményre, a többéves projektek végrehajtásának állapotára (beleértve az adott és az azt megelőző évekre vonatkozó költségvetés végrehajtásának egyértelmű bemutatását), valamint az eredményekre és a végrehajtásra. </p>
<p class="contents">Mindemellett a jelentés megállapítja, hogy a Számvevőszék véleménye szerint a közös vállalkozás éves beszámolója minden lényeges szempontból híven és pénzügyi szabályzatának, valamint a Bizottság számvitelért felelős tisztviselője által elfogadott számviteli szabályoknak megfelelően tükrözi a 2014. december 31-i pénzügyi helyzetet, illetve a tárgyévben lezajlott gazdasági és pénzforgalmi események eredményét. Éppen ezért szavazatommal támogattam a mentesítést biztosító jelentést.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit. ‒ </span>J'ai vote en faveur de la décharge et tiens à souligner le travail important et de qualité effectué par les experts S&amp;D tant en ce qui concerne les amendements et explications que durant les négociations.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Pavel Telička (ALDE), </span></span>  <span class="italic">in writing. ‒ </span>I voted in favour of granting the Innovative Medicines Initiative 2 Joint Undertaking discharge regarding the 2014 budget, since it complied with the required rules. The joint undertaking was thus able to contribute to speeding up the development of better and safer medicines, enable collaborative research projects and boost pharmaceutical innovation in Europe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119431.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ruža Tomašić (ECR), </span></span>  <span class="italic">napisan. ‒ </span>Zajedničko poduzeće za inicijativu za inovativne lijekove 2 treba rješavati uska grla u područjima javnog zdravstva koja ograničavaju učinkovitost i kvalitetu razvoja lijekova i plasiranja inovativnih lijekova na tržište. </p>
<p class="contents">Međutim, ukoliko djelatnost tog poduzeća nije transparentna, postoji mogućnost da njegov rad ne ide u korist građana država članica Europske unije. Smatram da sva poduzeća i svi segmenti proračuna Europske unije trebaju biti transparentni i održivi, stoga sam glasovala za odgađanje razrješnice za ovo poduzeće.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0562"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125104.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Romana Tomc (PPE), </span></span>  <span class="italic">pisno. ‒ </span>Poročilo o razrešnici glede izvrševanja proračuna Skupnega podjetja za pobudo za inovativna zdravila 2 (prej Skupno podjetje za izvajanje skupne tehnološke pobude za inovativna zdravila) sem podprla ob upoštevanju poročila Računskega sodišča o zaključnem računu Skupnega podjetja za pobudo za inovativna zdravila 2 (prej Skupno podjetje za izvajanje skupne tehnološke pobude za inovativna zdravila) za proračunsko leto 2014 z odgovori urada ter izjave o zanesljivosti računovodskih izkazov ter zakonitosti in pravilnosti z njimi povezanih transakcij, ki jo je za proračunsko leto 2014 v skladu s členom 287 Pogodbe o delovanju Evropske unije pripravilo Računsko sodišče.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0577"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/131749.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Estefanía Torres Martínez (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>Se ha votado a favor de la aprobación la gestión y del cierre de cuentas al no encontrarse irregularidades reseñables. Ahora bien, es preciso señalar, como en el caso restante de las Joint Undertakings, que mantenemos una posición crítica sobre las mismas en tanto que la participación público-privada supone una privatización de los rendimientos y una mercantilización de actividades de utilidad pública.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0593"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124705.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">István Ujhelyi (S&amp;D), </span></span>  <span class="italic">írásban. ‒ </span>Az innovatív gyógyszerek kutatására irányuló kezdeményezést megvalósító közös vállalkozást 2007 decemberében hozták létre tíz éves időszakra annak érdekében, hogy jelentősen javuljon a gyógyszerfejlesztés folyamatának hatékonysága és eredményessége, azzal a hosszú távú céllal, hogy a gyógyszeripari ágazat hatékonyabb és biztonságosabb innovatív gyógyszereket gyártson. A kapcsolódó jelentést támogattam.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0601"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/131507.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miguel Urbán Crespo (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>Se ha votado a favor de la aprobación la gestión y del cierre de cuentas al no encontrarse irregularidades reseñables. Ahora bien, es preciso señalar, como en el caso restante de las Joint Undertakings, que mantenemos una posición crítica sobre las mismas en tanto que la participación público-privada supone una privatización de los rendimientos y una mercantilización de actividades de utilidad pública.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0609"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124972.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ernest Urtasun (Verts/ALE), </span></span>  <span class="italic">por escrito. ‒ </span>He votado a favor de este informe porque creo que la evaluación del Parlamento Europeo sobre la gestión de la Empresa Común para la Iniciativa sobre Medicamentos Innovadores 2 es correcta.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0617"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125032.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ramón Luis Valcárcel Siso (PPE), </span></span>  <span class="italic">por escrito. ‒ </span>El informe anual de la Corte de Auditores sobre las cuentas anuales para el año financiero del año 2014 ha señalado que esta Empresa Común ha recibido una opinión positiva sobre la legalidad y la regularidad de las transacciones de sus cuentas. Por ello la comisión de control presupuestario aprobó por una amplia mayoría la gestión de esta agencia y considero necesario votar a favor de esta decisión.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0621"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125100.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miguel Viegas (GUE/NGL), </span></span>  <span class="italic">por escrito. ‒ </span>O Tribunal de Contas, no seu relatório sobre as contas anuais para o exercício de 2014, afirmou ter obtido garantias razoáveis de que as contas anuais do Gabinete são fiáveis e de que as operações subjacentes são legais e regulares.</p>
<p class="contents">Neste sentido, e não obstante as nossas reservas face ao caráter centralizador e federalista de grande parte destes organismos, não apresentamos nenhuma oposição de princípio a esta quitação.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0623"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125001.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Harald Vilimsky (ENF), </span></span>  <span class="italic">schriftlich. ‒ </span>In der Entschließung wird die mangelnde Transparenz in den Prozessen stark kritisiert, und es wird auch auf die fehlenden ex-ante Kontrollen aufmerksam gemacht. Deswegen habe ich dieser Entschließung zugestimmt.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0624"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124825.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Beatrix von Storch (EFDD), </span></span>  <span class="italic">schriftlich. ‒ </span>Den Bericht des Europäischen Parlaments über die Entlastung für die Ausführung des Haushaltsplans des Gemeinsamen Unternehmens „Initiative Innovative Arzneimittel 2“ (ehemals Gemeinsames Unternehmen zur Umsetzung der gemeinsamen Technologieinitiative für Innovative Arzneimittel) für das Haushaltsjahr 2014 habe ich abgelehnt. Ich lehne EU-Agenturen grundsätzlich ab. Joint Undertakings sind nicht nur in den allermeisten Fällen eine Verschwendung von Geld der Steuerzahler, sondern auch eine Überschreitung der Kompetenzen der EU und verletzen das Subsidiaritätsprinzip. Ich will nicht mehr EU, sondern weniger – also auch nicht mehr Joint Undertakings und mehr Geld für die EU, sondern weniger. Die EU sollte nicht privatwirtschaftlich tätig werden.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-1766-0750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96933.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Milan Zver (PPE), </span></span>  <span class="italic">pisno. ‒ </span>Podprl sem poročilo o razrešnici glede izvrševanja proračuna Skupnega podjetja za pobudo za inovativna zdravila 2 (prej Skupno podjetje za izvajanje skupne tehnološke pobude za inovativna zdravila) za proračunsko leto 2014, ker podaja utemeljene razloge in priporočila v prid podelitvi razrešnice.</p>
<p class="contents">Med drugim ugotavlja, da po mnenju Računskega sodišča zaključni račun Skupnega podjetja v vseh pomembnih vidikih ustrezno prikazuje njegovo finančno stanje na dan 31. decembra 2014 ter rezultate njegovega poslovanja in denarne tokove za leto, ki se je takrat končalo, v skladu z njegovimi finančnimi pravili in računovodskimi pravili, ki jih je sprejel računovodja Komisije.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
